Recruiting
Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas
ECM Therapeutics, Inc. · NCT07035925
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 10
- US sites recruiting
- 2
- Study start
- November 24, 2025
- Record last updated
- March 31, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Safety and Efficacy of ECMT-100 for the Treatment of Anorectal Fistulas
Being studied: ECMT-100
Conditions: Fistula in Ano
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male and female subjects at least 18 years of age.
- Provide informed consent
- Non-pregnant females
- Clinical diagnosis of 1 high transsphincteric anorectal fistula, with 1 internal opening and 1-2 external openings, with a single seton in place.
- Seton placement for a minimum of four (4) weeks
- Willingness to participate in post-operative follow-up evaluations.
Exclusion Criteria
- Inability to provide informed consent.
- Medical history of Crohn's disease/Ulcerative Colitis.
- Subjects with multiple fistula tracts (defined as >1 internal opening and/or >2 external openings), secondary tracts, horseshoe fistulas, J-pouch fistulas, superficial fistulas, ano/recto-vaginal fistulas or rectourethral fistulas.
- Previous fistulotomy/fistulectomy at the target treatment site (a history of these procedures at other locations is not exclusionary).
- Fistula of traumatic origin including obstetric.
- Evidence of ongoing local infection.
- Evidence of active abscess at the time of treatment.
- Chronic disease such as congestive heart failure, liver disease, renal disease, insulin dependent diabetes (as determined by A1C reading from past 6-12 months), or any chronic illness that may interfere with participation in this study.
- Active and unstable disease state or infection anywhere in the body per Investigator's evaluation and determination.
- Autoimmune disease that is not stable.
- Subjects who are immunocompromised such as known human immunodeficiency virus (HIV) or currently receiving chemotherapy or radiation therapy.
- Ongoing use of antiplatelet drugs. Subjects may be included in the study if antiplatelet drugs have been stopped for 5 to 7 days prior to surgery.
- Known coagulopathy (demonstrated by stated or medical record history of diagnosis)
- Pregnancy
- Previous history of radiation therapy in the area of the fistula.
- History of collagen disease.
- Known allergy to porcine products.
- Religious objection to use of porcine products.
Recruiting US locations
Dartmouth Hitchcock Medical Center
Lebanon, NH 03756
Site contact: Madison Duclos · 603-653-3607
University of Pittsburgh Medical Center
Pittsburgh, PA 15237
Site contact: Kim Sainiak · 412-647-1705 · sainiakks@upmc.edu
Study contacts (from the official record)
- Julie Cramer · 330-507-0801 · julie@clinicalresearchstrategies.com
- Cynthia Berringer · 412-638-9986 · cberringer@ecmtherapeutics.com